<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Int</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Int</journal-id><journal-title-group><journal-title>Kidney International</journal-title></journal-title-group><issn pub-type="ppub">0085-2538</issn><issn pub-type="epub">1523-1755</issn><publisher><publisher-name>International Society of Nephrology. Published by Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35421509</article-id><article-id pub-id-type="pmc">PMC9001011</article-id><article-id pub-id-type="pii">S0085-2538(22)00282-4</article-id><article-id pub-id-type="doi">10.1016/j.kint.2022.04.006</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Humoral response after a fourth &#x0201c;booster&#x0201d; dose of a Coronavirus disease 2019 vaccine following a 3-dose regimen of mRNA-based vaccination in dialysis patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Housset</surname><given-names>Pierre</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Kubab</surname><given-names>Sabah</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Hanafi</surname><given-names>Latifa</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Pardon</surname><given-names>Agathe</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Vittoz</surname><given-names>Nathalie</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Bozman</surname><given-names>Dogan-Firat</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Caudwell</surname><given-names>Val&#x000e9;rie</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Faucon</surname><given-names>Anne-Laure</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Department of Nephrology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France</aff><aff id="aff2"><label>2</label>Department of Microbiology, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France</aff><aff id="aff3"><label>3</label>Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale (INSERM) U1018, Clinical Epidemiology Unit, Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Villejuif, France</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Correspondence:</bold> Pierre Housset or Anne-Laure Faucon, Centre Hospitalier Sud-Francilien, Service de N&#x000e9;phrologie, 40 avenue Serge Dassault, 91100 Corbeil-Essonnes, France.</corresp></author-notes><pub-date pub-type="pmc-release"><day>12</day><month>4</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>6</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>12</day><month>4</month><year>2022</year></pub-date><volume>101</volume><issue>6</issue><fpage>1289</fpage><lpage>1290</lpage><permissions><copyright-statement>&#x000a9; 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>International Society of Nephrology</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p content-type="salutation">To the editor:</p><p id="p0010">Despite an initial satisfactory increase in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antispike antibody (Ab) titer after completing a 3-dose regimen in the first set of vaccination in dialysis patients,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Ab titer substantially decreases at 6 months in this population.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Other authors suggested that for the B.1.1.529 Omicron variant, 3 vaccine doses might be insufficient in in-center hemodialysis patients.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>
</p><p id="p0015">We assessed the dynamics of the anti&#x02013;SARS-CoV-2 spike protein S1 total Ig Ab (Roche Elecsys immunoassay<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref>) of both hemodialysis (n&#x000a0;= 17) and peritoneal dialysis (n&#x000a0;= 28) patients who received a 3-dose regimen of the mRNA BNT162b2 (Pfizer&#x02013;BioNTech), followed by a fourth &#x0201c;booster&#x0201d; dose of mRNA vaccine (BNT162b2, n&#x000a0;= 43, or mRNA-1273 [Moderna], n&#x000a0;= 2), after a median of 7.6 [interquartile range: 7.1; 7.8] months after the third dose (<xref rid="appsec1" ref-type="sec">Supplementary Figure&#x000a0;S1</xref>). Patients with a breakthrough infection (symptomatic or not) before the fourth dose were excluded (<xref rid="appsec1" ref-type="sec">Supplementary Figure&#x000a0;S2</xref>).</p><p id="p0020">In patients (57.8% men, median age 72 [56; 79] years), 15.6% had a history of immunosuppression (<xref rid="appsec1" ref-type="sec">Supplementary Table&#x000a0;S1</xref>). At 15 [14; 22] days after the fourth &#x0201c;booster&#x0201d; dose, antispike Ab titer significantly increased from 923 [369; 2019] to 21,883 [10,234; 42,870] AU/ml (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>
; <xref rid="appsec1" ref-type="sec">Supplementary Figure&#x000a0;S3</xref>), which corresponds to a 19-fold increase (median) in antispike Ab titer. Ab titer after the fourth dose was 3.4-fold higher (median) than the Ab peak reached after the third dose. Dose 4 appeared well-tolerated (<xref rid="appsec1" ref-type="sec">Supplementary Figure&#x000a0;S4</xref>), and no serious adverse event was observed. After the fourth dose, only 2 patients developed a breakthrough infection (vs. 7 cases of coronavirus disease 2019 after the third dose; <xref rid="appsec1" ref-type="sec">Supplementary Table&#x000a0;S2</xref>).<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p><bold>Kinetics of antispike antibodies.</bold> The figure shows the antispike antibody (Ab) levels before, and 1 (M1), 3 (M3), and 6 (M6) months after the third dose of the mRNA BNT162b2 vaccine, and after the fourth vaccine dose (BNT162b2 Pfizer&#x02013;BioNech or mRNA-1273 Moderna) in dialysis patients. Each point represents individual data. Antibody titers lower than 1 cannot be plotted in the graph because of the logarithm scale. The red points and vertical lines indicate the median with interquartile range. Conversion factor: 1 AU/ml&#x000a0;= 1.0288 BAU/ml.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0025">To conclude, our finding shows that a 3-dose regimen of an mRNA-based vaccine with a fourth booster dose appears to produce an important antibody response in dialysis patients, with a significant increase in antispike Ab titer. Long-term follow-up studies are needed to assess if this vaccination strategy elicits a durable and robust protective immune response against SARS-CoV-2 in dialysis patients.</p><sec id="sec1"><title>Data Statement</title><p id="p0030">The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><sec id="sec2"><title>Disclosure</title><p id="p0035">All the authors declared no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Bensouna</surname><given-names>I.</given-names></name><name><surname>Caudwell</surname><given-names>V.</given-names></name><name><surname>Kubab</surname><given-names>S.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 antibody response after a third dose of the BNT162b2 vaccine in patients receiving maintenance hemodialysis or peritoneal dialysis</article-title><source>Am J Kidney Dis</source><volume>79</volume><year>2022</year><fpage>185</fpage><lpage>192.e1</lpage><pub-id pub-id-type="pmid">34508833</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Housset</surname><given-names>P.</given-names></name><name><surname>Kubab</surname><given-names>S.</given-names></name><name><surname>Pardon</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Waning but persistent humoral response 6 months after the third dose of the mRNA BNT162b2 vaccine in hemodialysis and peritoneal dialysis patients</article-title><source>J&#x000a0;Nephrol</source><volume>35</volume><year>2022</year><fpage>783</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">35192157</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Carr</surname><given-names>E.J.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Harvey</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients</article-title><source>Lancet</source><volume>399</volume><year>2022</year><fpage>800</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">35065703</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Muench</surname><given-names>P.</given-names></name><name><surname>Jochum</surname><given-names>S.</given-names></name><name><surname>Wenderoth</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Development and validation of the Elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2</article-title><source>J&#x000a0;Clin Microbiol</source><volume>58</volume><year>2020</year><comment>e01694-20</comment></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary Material</title><p id="p0050">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary File (PDF)</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0040">The authors thank patients for their participation in the study.</p><sec id="sec3"><title>Author Contributions</title><p id="p0045">PH and A-LF researched the idea, created the study design, acquired the data, and analyzed and interpreted the data. A-LF provided statistical analyses. SK performed the antispike serology testing. Each author contributed important intellectual content during manuscript drafting or revision.</p></sec></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><p id="p0055">
<ext-link ext-link-type="doi" xlink:href="10.1016/j.kint.2022.04.006" id="intref0010">Supplementary File (PDF)</ext-link>
</p><p id="p0060">
<bold>Supplementary questionnaire on vaccine reactions and global tolerance after the fourth vaccine dose.</bold>
</p><p id="p0065"><bold>Table&#x000a0;S1.</bold> Characteristics of the study population.</p><p id="p0070"><bold>Table&#x000a0;S2.</bold> Characteristics of the patients with breakthrough coronavirus disease 2019 (COVID-19) after the third or the fourth vaccine dose during the fifth wave pandemic.</p><p id="p0075"><bold>Figure&#x000a0;S1.</bold> Vaccination strategy in dialysis patients.</p><p id="p0080"><bold>Figure&#x000a0;S2.</bold> Flowchart.</p><p id="p0085"><bold>Figure&#x000a0;S3.</bold> Kinetics of the antispike antibodies.</p><p id="p0090"><bold>Figure&#x000a0;S4.</bold> Self-reported tolerance.</p></fn></fn-group></back></article>
